The CAR-T drug is a "step-change" for patients with no other options, but it's too pricey to cover routinely, the cost watchdog said.
NICE said it's "actively engaging" with Biogen to address "uncertainties" about Spinraza's long-term effectiveness.
Vertex CEO Jeffrey Leiden took his fight over CF drug prices to U.K. Prime Minister Theresa May, urging her to step in.
Cost-effectiveness watchdog ICER routinely reviews new drug prices, but now it's aiming to unveil price hikes on older meds.
Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.
Patients in the U.K. won't have access to X-linked hypophosphatemia med Crysvita under a ruling by NICE.
After learning Aimovig's official price, ICER revised its work to conclude the migraine prevention drug is cost-effective when other options fail.
The U.S. cost-effectiveness watchdog suggests discounts of up to 77% on Vertex's cystic fibrosis drugs, but the company calls the process a "sham."
After a previous rejection and a discount offer, Roche's immunotherapy Tecentriq snagged an OK from England's influential cost-effectiveness watchdogs.